These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30615164)

  • 21. Age Group-Based Monitoring of the Progress in Measles and Rubella Elimination: Search for a Population Size/Density-Independent Parameter.
    Yoshikura H
    Jpn J Infect Dis; 2015; 68(6):533-5. PubMed ID: 26370432
    [No Abstract]   [Full Text] [Related]  

  • 22. [The German National Verification Committee for Measles and Rubella Elimination].
    Matysiak-Klose D; Razum O
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1293-6. PubMed ID: 23990092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerating measles and rubella elimination through research and innovation - Findings from the Measles & Rubella Initiative research prioritization process, 2016.
    Grant GB; Masresha BG; Moss WJ; Mulders MN; Rota PA; Omer SB; Shefer A; Kriss JL; Hanson M; Durrheim DN; Linkins R; Goodson JL
    Vaccine; 2019 Sep; 37(38):5754-5761. PubMed ID: 30904317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling and Managing the Risks of Measles and Rubella: A Global Perspective, Part I.
    Thompson KM; Cochi SL
    Risk Anal; 2016 Jul; 36(7):1288-96. PubMed ID: 27424287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eliminating measles and rubella in Europe.
    Allerberger F
    Clin Microbiol Infect; 2017 Aug; 23(8):502-503. PubMed ID: 28412385
    [No Abstract]   [Full Text] [Related]  

  • 26. Roadmap to elimination standard measles and rubella surveillance.
    Wkly Epidemiol Rec; 2017 Mar; 92(9-10):97-105. PubMed ID: 28262010
    [No Abstract]   [Full Text] [Related]  

  • 27. Surveillance and vaccination coverage of measles and rubella in Northern Italy.
    Amendola A; Bubba L; Piralla A; Binda S; Zanetti A; Pariani E; Ranghiero A; Premoli M; Pellegrinelli L; Coppola L; Gramegna M; Baldanti F; Zanetti A
    Hum Vaccin Immunother; 2015; 11(1):206-13. PubMed ID: 25483537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imported measles and rubella pose threat to US elimination of the diseases, says CDC report.
    McCarthy M
    BMJ; 2013 Dec; 347():f7373. PubMed ID: 24324216
    [No Abstract]   [Full Text] [Related]  

  • 29. The State of Measles and Rubella in the WHO European region.
    Muscat M; Ben Mamou M; Shefer A; Jankovic D; Deshevoy S; Butler R
    Rev Esp Salud Publica; 2015; 89(4):345-51. PubMed ID: 26580789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measles and rubella eradication.
    Hinman AR
    Vaccine; 2018 Jan; 36(1):1-3. PubMed ID: 29183733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can Norway be kept free from rubella and measles?
    Riise ØR; Rønning K; Dudman SG; Sandbu S
    Tidsskr Nor Laegeforen; 2017 Aug; 137(14-15):. PubMed ID: 28828847
    [No Abstract]   [Full Text] [Related]  

  • 32. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A measles eradication goal is upon us; can rubella and congenital rubella syndrome be far behind?
    Sniadack DH; Orenstein WA
    Vaccine; 2013 May; 31(24):2659-60. PubMed ID: 23602539
    [No Abstract]   [Full Text] [Related]  

  • 34. The end of measles and congenital rubella: an achievable dream?
    Adamo G; Sturabotti G; D'Andrea E; Baccolini V; Romano F; Iannazzo S; Marzuillo C; Villari P
    Ann Ig; 2017; 29(1):1-26. PubMed ID: 28067934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Verifying the Elimination of Measles and Rubella in the WHO European region: the Case of Spain.
    Santos Preciado JI
    Rev Esp Salud Publica; 2015; 89(4):353-5. PubMed ID: 26580790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measles and rubella elimination initiatives in the Americas: lessons learned and best practices.
    Castillo-Solorzano C; Marsigli C; Danovaro-Holliday MC; Ruiz-Matus C; Tambini G; Andrus JK
    J Infect Dis; 2011 Jul; 204 Suppl 1():S279-83. PubMed ID: 21666173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When, and how, should we introduce a combination measles-mumps-rubella (MMR) vaccine into the national childhood expanded immunization programme in South Africa?
    Cameron NA
    Vaccine; 2012 Sep; 30 Suppl 3():C58-60. PubMed ID: 22939023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: Background and summary.
    Orenstein WA; Cairns L; Hinman A; Nkowane B; Olivé JM; Reingold AL
    Vaccine; 2018 Jan; 36 Suppl 1():A35-A42. PubMed ID: 29307368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global measles and rubella laboratory network--update.
    World Health Organization
    Wkly Epidemiol Rec; 2005 Nov; 80(44):384-8. PubMed ID: 16300026
    [No Abstract]   [Full Text] [Related]  

  • 40. [Measles elimination programme on the world and Poland].
    Makówka A; Gut W; Litwińska B
    Przegl Epidemiol; 2007; 61(1):135-42. PubMed ID: 17702452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.